Hutchmed (HCM) announces that following the contract renewal with the China National Healthcare Security Administration, NHSA, the updated National Reimbursement Drug List effective on January 1, 2026 will continue to include ELUNATE, ORPATHYS and SULANDA. In addition, TAZVERIK will be included in the first edition of the National Commercial Health Insurance Innovative Drug List.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM:
- Hutchmed completes enrollment of SAFFRON Phase 3 trial of Orpathys+Tagrisso
- Hutchmed highlights pipeline, business progress at R&D Updates event
- Hutchmed’s HMPL-506 Study: A Potential Game-Changer in Hematological Malignancies
- Hutchmed’s Promising Study in Metastatic Pancreatic Cancer: A Potential Game Changer
- Hutchmed’s Phase III Study on HMPL-306: A Potential Game-Changer for AML Treatment